Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Down 82.4% in February

Bioxytran, Inc. (OTCMKTS:BIXT) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 7,200 shares, a decline of 82.4% from the January 31st total of 41,000 shares. Based on an average daily volume of 141,500 shares, the short-interest ratio is presently 0.1 days.

Bioxytran Stock Down 2.2 %

OTCMKTS:BIXT opened at $0.08 on Friday. Bioxytran has a 52 week low of $0.06 and a 52 week high of $0.15. The stock’s 50-day moving average price is $0.09 and its 200-day moving average price is $0.09. The stock has a market capitalization of $6.72 million, a PE ratio of -7.63 and a beta of -0.68.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.